(News Bulletin 247) – Jefferies confirms its buy advice on the stock with a price target of $350 while Leqembi has received full FDA approval (widely expected by the stock market according to the analyst).
Leqembi is the first and only approved treatment that Biogen says has been shown to reduce the rate of disease progression and slow cognitive and functional decline in adults with Alzheimer’s disease.
“We estimate Leqembi end-user sales of $30 million for 2023 and $298 million for 2024 (lower than forecast by $45 million/$408 million, respectively),” the analysts said.
Copyright (c) 2023 News Bulletin 247. All rights reserved.
I have over 8 years of experience working in the news industry. I have worked as a reporter, editor, and now managing editor at 247 News Agency. I am responsible for the day-to-day operations of the news website and overseeing all of the content that is published. I also write a column for the website, covering mostly market news.
